Dr. Moore Discusses Combinations in Ovarian Cancer

Kathleen N. Moore, MD
Published: Thursday, Feb 22, 2018



Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

There is a lot of basic and translational science that supports the use of combinations of immunotherapy and VEGF inhibitors, says Moore. VEGF is a proangiogenic molecule, but it is immuno-suppressive, so it directly and indirectly inhibits the immune response to cancer, Moore says. Combining a VEGF-targeted agent with an anti–PD-1/PD-L1 agent may prevent the tumor from evading immune response.

Additionally, there are several combinations that are of interest in ovarian cancer and other solid tumors. These combinations include immune agents plus antiangiogenic agents, PARP inhibitors or other DNA-damaged response inhibitors, cytotoxic chemotherapy, and immune agents in combinations with other immune agents. Moore says that investigators are capitalizing on different aspects of the immune system with these combinations.


Kathleen N. Moore, MD, assistant professor, Stephenson Cancer Center, The University of Oklahoma, discusses combinations in the treatment of patients with ovarian cancer.

There is a lot of basic and translational science that supports the use of combinations of immunotherapy and VEGF inhibitors, says Moore. VEGF is a proangiogenic molecule, but it is immuno-suppressive, so it directly and indirectly inhibits the immune response to cancer, Moore says. Combining a VEGF-targeted agent with an anti–PD-1/PD-L1 agent may prevent the tumor from evading immune response.

Additionally, there are several combinations that are of interest in ovarian cancer and other solid tumors. These combinations include immune agents plus antiangiogenic agents, PARP inhibitors or other DNA-damaged response inhibitors, cytotoxic chemotherapy, and immune agents in combinations with other immune agents. Moore says that investigators are capitalizing on different aspects of the immune system with these combinations.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Expert Perspectives to Incorporate Evidence on PARP Inhibitors into Practice and Optimize the Medical Management of Ovarian CancerOct 31, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x